MUSC Catalyst News

New RSV vaccine for pregnant women and people aged 60 and up arrives at MUSC Health. “No-brainer” for people who qualify, says expert.

Surveys at 12 cancer centers across the U.S. looked at cannabis usage among cancer patients.

LIFT scholars take flight in a new training course for researchers applying for their first NIH R01 grant.

As people with HIV live longer, they are more likely to get cancers that come with age but HIV might complicate treatment.

Scientists at MUSC Hollings Cancer Center think it's possible that CAR-T-cell therapy could be performed without lymphodepleting chemotherapy beforehand.

A new method to study changes in sugars coating immune cells could potentially identify novel biomarkers and detect cancer earlier.

Three Hollings members – an M.D., a D.D.S. and a Ph.D. – are pooling their expertise to develop a personalized vaccine to prevent oral cancer from returning.

MUSC Hollings Cancer Center awarded a number of pilot grants through the spring and summer to kickstart research projects on a range of topics.

The Clinical Trialist Training Program offers early-career clinicians the time and know-how to lead clinical trials.

MUSC team shows people with diverse childhood traumas are more likely to use cocaine and opioids. Trauma-focused interventions could help.